newsfilter
← Latest News
Business Wire·

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

-- Navenibart Demonstrated 6 Months of HAE Attack Prevention with 1 or 2 Doses -- -- 90-95% Mean Monthly Attack Rate Reduction Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 67% Attack-Free Rate Over 6 Months